Personalized Medicine with Advanced Analytics

Hongwei Wang (), Dai Feng and Yingyi Liu
Additional contact information
Hongwei Wang: Medical Affairs and Health Technology Assessment Statistics, Data and Statistical Sciences, AbbVie
Dai Feng: Medical Affairs and Health Technology Assessment Statistics, Data and Statistical Sciences, AbbVie
Yingyi Liu: Medical Affairs and Health Technology Assessment Statistics, Data and Statistical Sciences, AbbVie

A chapter in Real-World Evidence in Medical Product Development, 2023, pp 289-320 from Springer

Abstract: Abstract Practice of modern medicine demands personalized medicine (PM) to improve both quality of care and efficiency of the healthcare system. This is especially true as continued innovation in science and technology are delivering multiple interventions with different mechanism of actions for related comorbidity conditions. Real-world data (RWD) which typically includes a large, diverse, and heterogeneous patient population presents unique opportunity for PM research. In addition to natural history of disease and comparative effectiveness research, personalized medicine, that is who should initiate what and when, has been another central theme facing policy makers, physicians and patients. In the meantime, real-world studies (RWSs) usually come with high-dimensional and different types of covariates, relatively high proportion of missingness, more intercurrent events, a necessity to address confounding and quantify potential complex relationship between intervention and outcome. Therefore, advanced analytics are usually more suitable when addressing personalized medicine research questions. A few active areas include predictive modeling, natural language processing for free text to augment structured data, empirical subgroup identification, individualized treatment regime, and dynamic treatment regimens to define sequence of individually tailored decision rules. This chapter will review the latest developments in advanced analytics with the objective of facilitating adoption of personalized medicine and a focus of their relevance in generating robust real-world evidence (RWE).

Keywords: Personalized medicine; Conditional average treatment effect; Subgroup identification; Dynamic treatment regimes (search for similar items in EconPapers)
Date: 2023
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-3-031-26328-6_16

Ordering information: This item can be ordered from
http://www.springer.com/9783031263286

DOI: 10.1007/978-3-031-26328-6_16

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().